Published September 25, 2015
The University at Buffalo has been awarded a prestigious, four-year, $16 million Clinical and Translational Science Award (CTSA) from the National Institutes of Health (NIH) to speed the delivery of new drugs, diagnostics, and medical devices to patients. The grant will establish the UB Clinical and Translational Research Center as the hub of the Buffalo Translational Consortium. UB is the lead institution of the consortium in partnership with Roswell Park Cancer Institute, Great Lakes Health System, UBMD and community health organizations.
“This award recognizes and leverages the strong research and clinical collaborations UB and our partners on the Buffalo Niagara Medical Campus (BNMC) have built,” said UB President Satish K. Tripathi. “It gives us the ability to realize the value of these collaborations at an even higher level — empowering us as we move discoveries from the lab bench to the patient’s bedside, improve patient care and enhance economic development in Western New York by successfully commercializing scientific breakthroughs.”
The award puts UB and the Buffalo Translational Consortium, composed of clinical and research institutions on the BNMC, into an elite tier of institutions. “As home to the nation’s first cancer center, this prestigious federal grant recognizes the high-impact clinical research already taking place here and will provide a major boost to the collaborative synergy between the University at Buffalo, Roswell Park Cancer Institute, Great Lakes Health and other partners within the Buffalo Niagara Medical Campus,” said Rep. Brian Higgins, co-chair of the Congressional NIH Caucus. “This is a great tribute to UB and its partner institutions receiving the award, but the real excitement comes with the hope this grant provides to every patient and family touched by disease and anxiously awaiting the lifesaving treatments and cures this award makes possible.”
“This substantial federal funding will allow UB, Roswell, Great Lakes Health and their partners to be in the major leagues in the life-saving race for better treatments and cures for cancer, diabetes, Multiple Sclerosis, heart disease and other life-threatening illnesses,” said Sen. Charles E. Schumer. “Because of this funding, the world-class medical research happening in Western New York will be translated into real-life cancer treatments and solutions for patients around the world, which will create jobs, support the local economy and, most importantly – save lives. This is truly a game-changer for building an entirely new infrastructure to fight diseases in Western New York, and across our state.”
“This federal funding will enable the University at Buffalo to further enhance its medical and clinical research programs through partnerships with several health organizations,” said Sen. Kirsten Gillibrand. “The new Clinical and Translational Research Center will provide critical resources to help advance cutting edge research and scientific breakthroughs in patient health and wellness.”
“UB will now be competing for the highly selective awards for which only CTSA institutions may apply,” said Dr. Michael E. Cain, vice president for health sciences and dean of the UB School of Medicine and Biomedical Sciences. “Those grants will increase UB’s capacity for doing high-impact, clinical research, which will bring health care innovations to Buffalo so that people in our community can participate in, and benefit from, these groundbreaking studies.”
With the Jacobs School of Medicine and Biomedical Sciences as the main UB entity, the Buffalo Translational Consortium involves the university’s five health sciences schools, including the UB School of Public Health and Health Professions, and research institutes. Also partnering on the grant are local research institutes, such as the Hauptman-Woodward Medical Research Institute, as well as community partners, such as the P2 Collaborative, HEALTHeLINK, UNYNET, the New York State Area Health Education Center System and the Patient Voices Network.”